{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Podolski-Renic A"],"funding":["Science Fund of the Republic of Serbia"],"pagination":["189"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11859366"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["17(2)"],"pubmed_abstract":["<b>Background/Objectives</b>: This study explores the potential of LB-100 (a protein phosphatase 2A-PP2A inhibitor) combined with adavosertib (a WEE1 kinase inhibitor) and doxorubicin (DOX), to overcome multidrug resistance (MDR) in cancer cells and enhance treatment efficacy. <b>Methods</b>: We evaluated LB-100 combinations with adavosertib and DOX in patient-derived glioblastoma and non-small cell lung carcinoma cells (NSCLCs) using a real-time cell analyzer. Effectiveness was also assessed through immunofluorescence assay, and interactions were analyzed via SynergyFinder+. We also examined P-glycoprotein (P-gp) expression and drug resistance genes' expression in MDR glioblastoma and NSCLCs after LB-100 treatment, as well as LB-100 sensitizing effect on DOX and DOX accumulation. <b>Resul"],"journal":["Pharmaceutics"],"pubmed_title":["LB-100 Enhances Drugs Efficacy Through Inhibition of P-Glycoprotein Expression in Multidrug-Resistant Glioblastoma and Non-Small Cell Lung Carcinoma Cellular Models."],"pmcid":["PMC11859366"],"funding_grant_id":["#7739737"],"pubmed_authors":["Podolski-Renic A","Jovanovic Stojanov S","Grozdanic M","Pesic M","Dragoj M","Lupsic E","Nikolic I","Dinic J","Chigriai M"],"additional_accession":[]},"is_claimable":false,"name":"LB-100 Enhances Drugs Efficacy Through Inhibition of P-Glycoprotein Expression in Multidrug-Resistant Glioblastoma and Non-Small Cell Lung Carcinoma Cellular Models.","description":"<b>Background/Objectives</b>: This study explores the potential of LB-100 (a protein phosphatase 2A-PP2A inhibitor) combined with adavosertib (a WEE1 kinase inhibitor) and doxorubicin (DOX), to overcome multidrug resistance (MDR) in cancer cells and enhance treatment efficacy. <b>Methods</b>: We evaluated LB-100 combinations with adavosertib and DOX in patient-derived glioblastoma and non-small cell lung carcinoma cells (NSCLCs) using a real-time cell analyzer. Effectiveness was also assessed through immunofluorescence assay, and interactions were analyzed via SynergyFinder+. We also examined P-glycoprotein (P-gp) expression and drug resistance genes' expression in MDR glioblastoma and NSCLCs after LB-100 treatment, as well as LB-100 sensitizing effect on DOX and DOX accumulation. <b>Resul","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Feb","modification":"2025-04-22T18:57:50.951Z","creation":"2025-04-06T02:38:05.428Z"},"accession":"S-EPMC11859366","cross_references":{"pubmed":["40006556"],"doi":["10.3390/pharmaceutics17020189"]}}